364 filings
Page 2 of 19
6-K
oj5vfedxzd0x
30 Aug 23
Current report (foreign)
6:45am
6-K
hunrujn4o5 qya
8 Aug 23
Current report (foreign)
5:25pm
6-K
2apwnt7 539gpp45
17 Jul 23
BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic
7:10am
6-K
zp8e9jmgbz08 iz
23 Jun 23
Notice of Annual General Meeting of Shareholders
4:16pm
6-K
s9r5mf odnh6ab
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
k6u mk8l3b3otmnw9
25 Apr 23
Current report (foreign)
7:07am
6-K
xfwkz
17 Apr 23
BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating
11:08am
6-K
3vj7uogl4m yesq7
22 Mar 23
BioLineRx Reports 2022 Financial Results and Recent Corporate
7:31am
6-K
xi3y8jjiynao ev
6 Mar 23
BioLineRx Announces Clinical Trial Collaboration with Washington University School of
7:09am
6-K
3v2u9 nhdxfmx4moi2y2
4 Jan 23
BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer
7:06am
6-K
8bgmn
20 Dec 22
BioLineRx Announces Results from Phase 1/2a Study of Investigational
7:08am
6-K
c5xrunn5oqfao8
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
6-K
fblipgt6gzem
10 Nov 22
Current report (foreign)
7:08am
6-K
xba99e078bm2giw5s
4 Nov 22
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
4:35pm
6-K
xgkfh
3 Nov 22
BioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Multiple Myeloma
9:20am
6-K
91ik c1967m
27 Sep 22
BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization
7:00am
6-K
u10vxn9 r2trr0vn09
21 Sep 22
Current report (foreign)
8:00am
6-K
3zn2i2u693q 4y3
19 Sep 22
BioLineRx Announces $15 Million Registered Direct Offering
8:08am
6-K
sfhqakm844
15 Sep 22
Current report (foreign)
8:39am
6-K
y88tvufmobbj1
12 Sep 22
BioLineRx Announces Submission of New Drug Application
8:16am